Cargando…

Gastric and intestinal phenotypic marker expression in gastric carcinomas and recurrence pattern after surgery-immunohistochemical analysis of 213 lesions-

Both gastric and intestinal phenotypic markers are known to be expressed in gastric carcinomas, irrespective of their histologic type. In the present study, the relation between gastric and intestinal phenotypic marker expression in gastric carcinomas and the recurrence pattern after surgery was exa...

Descripción completa

Detalles Bibliográficos
Autores principales: Tajima, Y, Yamazaki, K, Nishino, N, Morohara, K, Yamazaki, T, Kaetsu, T, Suzuki, S, Kawamura, M, Kumagai, K, Kusano, M
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 2004
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2409904/
https://www.ncbi.nlm.nih.gov/pubmed/15354218
http://dx.doi.org/10.1038/sj.bjc.6602147
_version_ 1782155894710075392
author Tajima, Y
Yamazaki, K
Nishino, N
Morohara, K
Yamazaki, T
Kaetsu, T
Suzuki, S
Kawamura, M
Kumagai, K
Kusano, M
author_facet Tajima, Y
Yamazaki, K
Nishino, N
Morohara, K
Yamazaki, T
Kaetsu, T
Suzuki, S
Kawamura, M
Kumagai, K
Kusano, M
author_sort Tajima, Y
collection PubMed
description Both gastric and intestinal phenotypic markers are known to be expressed in gastric carcinomas, irrespective of their histologic type. In the present study, the relation between gastric and intestinal phenotypic marker expression in gastric carcinomas and the recurrence pattern after surgery was examined. The phenotypic marker expression of the tumour was determined by examining the expression of human gastric mucin (HGM), MUC6, MUC2 and CD10 in 213 advanced gastric carcinomas in 213 patients who had undergone a curative resection (97 died from recurrent gastric carcinoma and 116 were alive without recurrence at the end of the follow-up period). Tumours were classified into gastric (G), gastric and intestinal mixed (GI), intestinal (I) or unclassified (UC) phenotypes according to the immunopositivity of HGM, MUC6, MUC2 and CD10 stainings. The incidence of HGM-positive tumours and MUC2-negative tumours was significantly higher in tumours with peritoneal recurrence than in tumours without recurrence (73.3%, 44 out of 60 cases vs 54.3%, 63 out of 116 (P=0.022); and 70.0%, 42 out of 60 vs 38.8%, 45 out of 116 (P=0.0002), respectively). The incidence of G-phenotype tumours was also significantly higher in tumours with peritoneal recurrence than in tumours without recurrence (58.3%, 35 out of 60 cases vs 28.4%, 33 out of 116 (P=0.0002)). The incidence of MUC2-negative tumours and CD10-positive tumours was significantly higher in tumours with haematogenous recurrence than in tumours without recurrence (62.5%, 20 out of 32 cases vs 38.8%, 45 out of 116 (P=0.028); and 43.8%, 14 out of 32 vs 23.3%, 27 out of 116 (P=0.039); respectively). Our present findings show that the gastric and intestinal phenotypic marker expression of the tumour, determined by immunohistochemical staining for HGM, MUC6, MUC2 and CD10, can be used to predict the pattern of gastric carcinoma recurrence after curative resection.
format Text
id pubmed-2409904
institution National Center for Biotechnology Information
language English
publishDate 2004
publisher Nature Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-24099042009-09-10 Gastric and intestinal phenotypic marker expression in gastric carcinomas and recurrence pattern after surgery-immunohistochemical analysis of 213 lesions- Tajima, Y Yamazaki, K Nishino, N Morohara, K Yamazaki, T Kaetsu, T Suzuki, S Kawamura, M Kumagai, K Kusano, M Br J Cancer Molecular and Cellular Pathology Both gastric and intestinal phenotypic markers are known to be expressed in gastric carcinomas, irrespective of their histologic type. In the present study, the relation between gastric and intestinal phenotypic marker expression in gastric carcinomas and the recurrence pattern after surgery was examined. The phenotypic marker expression of the tumour was determined by examining the expression of human gastric mucin (HGM), MUC6, MUC2 and CD10 in 213 advanced gastric carcinomas in 213 patients who had undergone a curative resection (97 died from recurrent gastric carcinoma and 116 were alive without recurrence at the end of the follow-up period). Tumours were classified into gastric (G), gastric and intestinal mixed (GI), intestinal (I) or unclassified (UC) phenotypes according to the immunopositivity of HGM, MUC6, MUC2 and CD10 stainings. The incidence of HGM-positive tumours and MUC2-negative tumours was significantly higher in tumours with peritoneal recurrence than in tumours without recurrence (73.3%, 44 out of 60 cases vs 54.3%, 63 out of 116 (P=0.022); and 70.0%, 42 out of 60 vs 38.8%, 45 out of 116 (P=0.0002), respectively). The incidence of G-phenotype tumours was also significantly higher in tumours with peritoneal recurrence than in tumours without recurrence (58.3%, 35 out of 60 cases vs 28.4%, 33 out of 116 (P=0.0002)). The incidence of MUC2-negative tumours and CD10-positive tumours was significantly higher in tumours with haematogenous recurrence than in tumours without recurrence (62.5%, 20 out of 32 cases vs 38.8%, 45 out of 116 (P=0.028); and 43.8%, 14 out of 32 vs 23.3%, 27 out of 116 (P=0.039); respectively). Our present findings show that the gastric and intestinal phenotypic marker expression of the tumour, determined by immunohistochemical staining for HGM, MUC6, MUC2 and CD10, can be used to predict the pattern of gastric carcinoma recurrence after curative resection. Nature Publishing Group 2004-10-04 2004-08-31 /pmc/articles/PMC2409904/ /pubmed/15354218 http://dx.doi.org/10.1038/sj.bjc.6602147 Text en Copyright © 2004 Cancer Research UK https://creativecommons.org/licenses/by/4.0/This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material.If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit https://creativecommons.org/licenses/by/4.0/.
spellingShingle Molecular and Cellular Pathology
Tajima, Y
Yamazaki, K
Nishino, N
Morohara, K
Yamazaki, T
Kaetsu, T
Suzuki, S
Kawamura, M
Kumagai, K
Kusano, M
Gastric and intestinal phenotypic marker expression in gastric carcinomas and recurrence pattern after surgery-immunohistochemical analysis of 213 lesions-
title Gastric and intestinal phenotypic marker expression in gastric carcinomas and recurrence pattern after surgery-immunohistochemical analysis of 213 lesions-
title_full Gastric and intestinal phenotypic marker expression in gastric carcinomas and recurrence pattern after surgery-immunohistochemical analysis of 213 lesions-
title_fullStr Gastric and intestinal phenotypic marker expression in gastric carcinomas and recurrence pattern after surgery-immunohistochemical analysis of 213 lesions-
title_full_unstemmed Gastric and intestinal phenotypic marker expression in gastric carcinomas and recurrence pattern after surgery-immunohistochemical analysis of 213 lesions-
title_short Gastric and intestinal phenotypic marker expression in gastric carcinomas and recurrence pattern after surgery-immunohistochemical analysis of 213 lesions-
title_sort gastric and intestinal phenotypic marker expression in gastric carcinomas and recurrence pattern after surgery-immunohistochemical analysis of 213 lesions-
topic Molecular and Cellular Pathology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2409904/
https://www.ncbi.nlm.nih.gov/pubmed/15354218
http://dx.doi.org/10.1038/sj.bjc.6602147
work_keys_str_mv AT tajimay gastricandintestinalphenotypicmarkerexpressioningastriccarcinomasandrecurrencepatternaftersurgeryimmunohistochemicalanalysisof213lesions
AT yamazakik gastricandintestinalphenotypicmarkerexpressioningastriccarcinomasandrecurrencepatternaftersurgeryimmunohistochemicalanalysisof213lesions
AT nishinon gastricandintestinalphenotypicmarkerexpressioningastriccarcinomasandrecurrencepatternaftersurgeryimmunohistochemicalanalysisof213lesions
AT moroharak gastricandintestinalphenotypicmarkerexpressioningastriccarcinomasandrecurrencepatternaftersurgeryimmunohistochemicalanalysisof213lesions
AT yamazakit gastricandintestinalphenotypicmarkerexpressioningastriccarcinomasandrecurrencepatternaftersurgeryimmunohistochemicalanalysisof213lesions
AT kaetsut gastricandintestinalphenotypicmarkerexpressioningastriccarcinomasandrecurrencepatternaftersurgeryimmunohistochemicalanalysisof213lesions
AT suzukis gastricandintestinalphenotypicmarkerexpressioningastriccarcinomasandrecurrencepatternaftersurgeryimmunohistochemicalanalysisof213lesions
AT kawamuram gastricandintestinalphenotypicmarkerexpressioningastriccarcinomasandrecurrencepatternaftersurgeryimmunohistochemicalanalysisof213lesions
AT kumagaik gastricandintestinalphenotypicmarkerexpressioningastriccarcinomasandrecurrencepatternaftersurgeryimmunohistochemicalanalysisof213lesions
AT kusanom gastricandintestinalphenotypicmarkerexpressioningastriccarcinomasandrecurrencepatternaftersurgeryimmunohistochemicalanalysisof213lesions